Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists



Status:Archived
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:March 2009
End Date:July 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Rabbit Anti-thymocyte Globulin Versus IL2 Receptor Antagonists in Combination With Tacrolimus, Corticosteroids and Mycophenolate Mofetil in a Predominantly High Risk Kidney Transplant Population.


The purpose of this study is to evaluate the safety and efficacy of induction therapy with
Thymoglobulin in comparison with IL2 receptor antagonists (daclizumab or basiliximab).


A 12 month, prospective, randomized, single center, open-label study to evaluate the safety
and efficacy of Rabbit anti-thymocyte globulin versus IL2 receptor antagonists in
combination with tacrolimus, corticosteroids and mycophenolate mofetil in a predominantly
high risk kidney transplant population.


We found this trial at
1
site
Medical University of South Carolina
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials